.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
US Department of Justice
Deloitte
Daiichi Sankyo
Cipla
Queensland Health
McKesson
Citi
Covington
Federal Trade Commission

Generated: July 22, 2017

DrugPatentWatch Database Preview

Mesalamine - Generic Drug Details

« Back to Dashboard

What are the generic sources for mesalamine and what is the scope of mesalamine freedom to operate?

Mesalamine
is the generic ingredient in ten branded drugs marketed by Shire, Valeant Pharms Intl, Apil, Mylan Speciality Lp, Meda Pharms, Zydus Pharms Usa Inc, G And W Labs Inc, Perrigo Israel, Forest Labs Llc, and Mylan Pharms Inc, and is included in thirteen NDAs. There are sixteen patents protecting this compound and six Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Mesalamine has ninety-five patent family members in twenty-seven countries.

There are twenty-seven drug master file entries for mesalamine. Twenty-two suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: mesalamine

Tradenames:10
Patents:16
Applicants:10
NDAs:13
Drug Master File Entries: see list27
Suppliers / Packagers: see list22
Bulk Api Vendors: see list112
Clinical Trials: see list73
Patent Applications: see list6,098
Therapeutic Class:Inflammatory Bowel Disease Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:mesalamine at DailyMed

Pharmacology for Ingredient: mesalamine

Ingredient-typeAminosalicylic Acids
Drug ClassAminosalicylate

Tentative approvals for MESALAMINE

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe1000MGSUPPOSITORY;RECTAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms Intl
APRISO
mesalamine
CAPSULE, EXTENDED RELEASE;ORAL022301-001Oct 31, 2008RXYesYes8,911,778► SubscribeY ► Subscribe
Forest Labs Llc
CANASA
mesalamine
SUPPOSITORY;RECTAL021252-002Nov 5, 2004ABRXYesYes8,217,083► SubscribeY ► Subscribe
Apil
ASACOL HD
mesalamine
TABLET, DELAYED RELEASE;ORAL021830-001May 29, 2008RXYesYes9,089,492► SubscribeY ► Subscribe
Perrigo Israel
MESALAMINE
mesalamine
ENEMA;RECTAL076751-001Sep 17, 2004ABRXNoNo► Subscribe► Subscribe
Valeant Pharms Intl
APRISO
mesalamine
CAPSULE, EXTENDED RELEASE;ORAL022301-001Oct 31, 2008RXYesYes8,940,328► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: mesalamine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Shire
PENTASA
mesalamine
CAPSULE, EXTENDED RELEASE;ORAL020049-001May 10, 19934,980,173► Subscribe
Apil
ASACOL HD
mesalamine
TABLET, DELAYED RELEASE;ORAL021830-001May 29, 20085,541,170► Subscribe
Apil
ASACOL HD
mesalamine
TABLET, DELAYED RELEASE;ORAL021830-001May 29, 20085,541,171► Subscribe
Apil
DELZICOL
mesalamine
CAPSULE, DELAYED RELEASE;ORAL204412-001Feb 1, 20135,541,170► Subscribe
Shire
PENTASA
mesalamine
CAPSULE, EXTENDED RELEASE;ORAL020049-001May 10, 19934,496,553► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: mesalamine

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,277,412 Pellet-type formulation intended for treating the intestinal tract► Subscribe
7,547,451Pellet formulation for the treatment of the intestinal tract► Subscribe
7,541,384Mesalamine suppository► Subscribe
8,217,082Reduced irritant enema for the treatment of inflammatory bowel disease (IBD)► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: mesalamine

Country Document Number Estimated Expiration
Mexico2012006902► Subscribe
ItalyMI991316► Subscribe
MexicoPA04004747► Subscribe
Spain2194732► Subscribe
Turkey200200561► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Cipla
Daiichi Sankyo
Deloitte
Federal Trade Commission
Fish and Richardson
Argus Health
Julphar
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot